REFERENCES
1. Priori SG and Blomström-Lundqvist C. 2015 European Society of
Cardiology Guidelines for the management of patients with ventricular
arrhythmias and the prevention of sudden cardiac death summarized by
co-chairs. Eur Heart J . 2015;36:2757-9.
2. Postema PG. About Brugada syndrome and its prevalence.Europace . 2012;14:925-8.
3. Sangwatanaroj S, Prechawat S, Sunsaneewitayakul B, Sitthisook S,
Tosukhowong P and Tungsanga K. New electrocardiographic leads and the
procainamide test for the detection of the Brugada sign in sudden
unexplained death syndrome survivors and their relatives. Eur
Heart J . 2001;22:2290-6.
4. Casado-Arroyo R, Berne P, Rao JY, Rodriguez-Mañero M, Levinstein M,
Conte G, Sieira J, Namdar M, Ricciardi D, Chierchia GB, de Asmundis C,
Pappaert G, La Meir M, Wellens F, Brugada J and Brugada P. Long-Term
Trends in Newly Diagnosed Brugada Syndrome: Implications for Risk
Stratification. J Am Coll Cardiol . 2016;68:614-623.
5. Brugada J, Campuzano O, Arbelo E, Sarquella-Brugada G and Brugada R.
Present Status of Brugada Syndrome: JACC State-of-the-Art Review.J Am Coll Cardiol . 2018;72:1046-1059.
6. Vutthikraivit W, Rattanawong P, Putthapiban P, Sukhumthammarat W,
Vathesatogkit P, Ngarmukos T and Thakkinstian A. Worldwide Prevalence of
Brugada Syndrome: A Systematic Review and Meta-Analysis. Acta
Cardiol Sin . 2018;34:267-277.
7. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ,
Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger
CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ
and Page RL. 2017 AHA/ACC/HRS guideline for management of patients with
ventricular arrhythmias and the prevention of sudden cardiac death:
Executive summary: A Report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice
Guidelines and the Heart Rhythm Society. Heart Rhythm .
2018;15:e190-e252.
8. Gonzalez Corcia MC, Sieira J, Pappaert G, de Asmundis C, Chierchia
GB, La Meir M, Sarkozy A and Brugada P. Implantable
Cardioverter-Defibrillators in Children and Adolescents With
Brugada Syndrome. J Am Coll Cardiol . 2018;71:148-157.
9. Ohkubo K, Watanabe I, Okumura Y, Ashino S, Kofune M, Nagashima K,
Kofune T, Nakai T, Kunimoto S, Kasamaki Y and Hirayama A. Prolonged QRS
duration in lead V2 and risk of life-threatening ventricular Arrhythmia
in patients with Brugada syndrome. Int Heart J . 2011;52:98-102.
10. Priori SG, Gasparini M, Napolitano C, Della Bella P, Ottonelli AG,
Sassone B, Giordano U, Pappone C, Mascioli G, Rossetti G, De Nardis R
and Colombo M. Risk stratification in Brugada syndrome: results of the
PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry.J Am Coll Cardiol . 2012;59:37-45.
11. Babai Bigi MA, Aslani A and Shahrzad S. aVR sign as a risk factor
for life-threatening arrhythmic events in patients with Brugada
syndrome. Heart Rhythm . 2007;4:1009-12.
12. Calò L, Giustetto C, Martino A, Sciarra L, Cerrato N, Marziali M,
Rauzino J, Carlino G, de Ruvo E, Guerra F, Rebecchi M, Lanzillo C,
Anselmino M, Castro A, Turreni F, Penco M, Volpe M, Capucci A and Gaita
F. A New Electrocardiographic Marker of Sudden Death in Brugada
Syndrome: The S-Wave in Lead I. J Am Coll Cardiol .
2016;67:1427-1440.
13. Rolf S, Bruns HJ, Wichter T, Kirchhof P, Ribbing M, Wasmer K, Paul
M, Breithardt G, Haverkamp W and Eckardt L. The ajmaline challenge in
Brugada syndrome: diagnostic impact, safety, and recommended protocol.Eur Heart J . 2003;24:1104-12.
14. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R,
Corrado D, Gussak I, LeMarec H, Nademanee K, Perez Riera AR, Shimizu W,
Schulze-Bahr E, Tan H and Wilde A. Brugada syndrome: report of the
second consensus conference. Heart Rhythm . 2005;2:429-40.
15. Sarquella-Brugada G, Campuzano O, Arbelo E, Brugada J and Brugada R.
Brugada syndrome: clinical and genetic findings. Genet Med .
2016;18:3-12.
16. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody
WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL and Committee
ALQA. Standards and guidelines for the interpretation of sequence
variants: a joint consensus recommendation of the American College of
Medical Genetics and Genomics and the Association for Molecular
Pathology. Genet Med . 2015;17:405-24.
17. Milman A, Andorin A, Gourraud JB, Sacher F, Mabo P, Kim SH, Maeda S,
Takahashi Y, Kamakura T, Aiba T, Conte G, Juang JJM, Leshem E, Rahkovich
M, Hochstadt A, Mizusawa Y, Postema PG, Arbelo E, Huang Z, Denjoy I,
Giustetto C, Wijeyeratne YD, Napolitano C, Michowitz Y, Brugada R,
Casado-Arroyo R, Champagne J, Calo L, Sarquella-Brugada G, Tfelt-Hansen
J, Priori SG, Takagi M, Veltmann C, Delise P, Corrado D, Behr ER, Gaita
F, Yan GX, Brugada J, Leenhardt A, Wilde AAM, Brugada P, Kusano KF,
Hirao K, Nam GB, Probst V and Belhassen B. Age of First Arrhythmic Event
in Brugada Syndrome: Data From the SABRUS (Survey on Arrhythmic Events
in Brugada Syndrome) in 678 Patients. Circ Arrhythm
Electrophysiol . 2017;10.
18. Probst V, Veltmann C, Eckardt L, Meregalli PG, Gaita F, Tan HL,
Babuty D, Sacher F, Giustetto C, Schulze-Bahr E, Borggrefe M,
Haissaguerre M, Mabo P, Le Marec H, Wolpert C and Wilde AA. Long-term
prognosis of patients diagnosed with Brugada syndrome: Results from the
FINGER Brugada Syndrome Registry. Circulation . 2010;121:635-43.
19. Sieira J, Conte G, Ciconte G, Chierchia GB, Casado-Arroyo R,
Baltogiannis G, Di Giovanni G, Saitoh Y, Juliá J, Mugnai G, La Meir M,
Wellens F, Czapla J, Pappaert G, de Asmundis C and Brugada P. A score
model to predict risk of events in patients with Brugada Syndrome.Eur Heart J . 2017;38:1756-1763.
20. Miyamoto K, Yokokawa M, Tanaka K, Nagai T, Okamura H, Noda T, Satomi
K, Suyama K, Kurita T, Aihara N, Kamakura S and Shimizu W. Diagnostic
and prognostic value of a type 1 Brugada electrocardiogram at higher
(third or second) V1 to V2 recording in men with Brugada syndrome.Am J Cardiol . 2007;99:53-7.
21. Curcio A, Mazzanti A, Bloise R, Monteforte N, Indolfi C, Priori SG
and Napolitano C. Clinical Presentation and Outcome of Brugada Syndrome
Diagnosed With the New 2013 Criteria. J Cardiovasc
Electrophysiol . 2016;27:937-43.
22. Sacher F, Probst V, Maury P, Babuty D, Mansourati J, Komatsu Y,
Marquie C, Rosa A, Diallo A, Cassagneau R, Loizeau C, Martins R, Field
ME, Derval N, Miyazaki S, Denis A, Nogami A, Ritter P, Gourraud JB,
Ploux S, Rollin A, Zemmoura A, Lamaison D, Bordachar P, Pierre B, Jaïs
P, Pasquié JL, Hocini M, Legal F, Defaye P, Boveda S, Iesaka Y, Mabo P
and Haïssaguerre M. Outcome after implantation of a
cardioverter-defibrillator in patients with Brugada syndrome: a
multicenter study-part 2. Circulation . 2013;128:1739-47.
23. Tse G, Gong M, Meng L, Wong CW, Georgopoulos S, Bazoukis G, Wong
MCS, Letsas KP, Vassiliou VS, Xia Y, Baranchuk AM, Yan GX and Liu T.
Meta-analysis of T. J Electrocardiol . 2018;51:396-401.
24. Morita H, Watanabe A, Kawada S, Miyamoto M, Morimoto Y, Nakagawa K,
Nishii N, Nakamura K and Ito H. Identification of electrocardiographic
risk markers for the initial and recurrent episodes of ventricular
fibrillation in patients with Brugada syndrome. J Cardiovasc
Electrophysiol . 2018;29:107-114.
25. Sieira J, Conte G, Ciconte G, de Asmundis C, Chierchia GB,
Baltogiannis G, Di Giovanni G, Saitoh Y, Irfan G, Casado-Arroyo R, Juliá
J, La Meir M, Wellens F, Wauters K, Van Malderen S, Pappaert G and
Brugada P. Prognostic value of programmed electrical stimulation in
Brugada syndrome: 20 years experience. Circ Arrhythm
Electrophysiol . 2015;8:777-84.
26. Denham NC, Pearman CM, Ding WY, Waktare J, Gupta D, Snowdon R, Hall
M, Cooper R, Modi S, Todd D and Mahida S. Systematic re-evaluation of
SCN5A variants associated with Brugada syndrome. J Cardiovasc
Electrophysiol . 2019;30:118-127.
27. Walsh R and Wilde AAM. SCN5A variants in Brugada syndrome: True,
true false, or false true. J Cardiovasc Electrophysiol .
2019;30:128-131.
28. Bébarová M, O’Hara T, Geelen JL, Jongbloed RJ, Timmermans C, Arens
YH, Rodriguez LM, Rudy Y and Volders PG. Subepicardial phase 0 block and
discontinuous transmural conduction underlie right precordial ST-segment
elevation by a SCN5A loss-of-function mutation. Am J Physiol Heart
Circ Physiol . 2008;295:H48-58.
29. Yamagata K, Horie M, Aiba T, Ogawa S, Aizawa Y, Ohe T, Yamagishi M,
Makita N, Sakurada H, Tanaka T, Shimizu A, Hagiwara N, Kishi R, Nakano
Y, Takagi M, Makiyama T, Ohno S, Fukuda K, Watanabe H, Morita H, Hayashi
K, Kusano K, Kamakura S, Yasuda S, Ogawa H, Miyamoto Y, Kapplinger JD,
Ackerman MJ and Shimizu W. Genotype-Phenotype Correlation of.Circulation . 2017;135:2255-2270.
30. Lizotte E, Junttila MJ, Dube MP, Hong K, Benito B, DE Zutter M,
Henkens S, Sarkozy A, Huikuri HV, Towbin J, Vatta M, Brugada P, Brugada
J and Brugada R. Genetic modulation of brugada syndrome by a common
polymorphism. J Cardiovasc Electrophysiol . 2009;20:1137-41.
31. Matsumura H, Nakano Y, Ochi H, Onohara Y, Sairaku A, Tokuyama T,
Tomomori S, Motoda C, Amioka M, Hironobe N, Toshishige M, Takahashi S,
Imai K, Sueda T, Chayama K and Kihara Y. H558R, a common SCN5A
polymorphism, modifies the clinical phenotype of Brugada syndrome by
modulating DNA methylation of SCN5A promoters. J Biomed Sci .
2017;24:91.